Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00763321
Recruitment Status : Completed
First Posted : September 30, 2008
Results First Posted : December 23, 2013
Last Update Posted : February 6, 2014
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor);   Primary Purpose: Treatment
Condition Chronic Low Back Pain
Interventions Drug: ABT-712
Drug: Placebo
Enrollment 287
Recruitment Details  
Pre-assignment Details Out of the 287 participants enrolled in the study, 285 participants were treated; 2 participants did not receive treatment during the open-label treatment period.
Arm/Group Title Open-label ABT-712 Double-blind ABT-712 Double-blind Placebo
Hide Arm/Group Description 2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period). 2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period). 2 placebo tablets, twice daily, for 4 weeks (double-blind period).
Period Title: Open-label Period
Started 285 0 0
Completed 222 0 0
Not Completed 63 0 0
Reason Not Completed
Adverse Event             24             0             0
Lost to Follow-up             14             0             0
Withdrawal by Subject             7             0             0
Subject noncompliant             7             0             0
Did not meet DB randomization criteria             5             0             0
Lack of Efficacy             2             0             0
Other             4             0             0
Period Title: Double-blind Period
Started 0 109 113
Completed 0 88 84
Not Completed 0 21 29
Reason Not Completed
Lack of Efficacy             0             9             17
Adverse Event             0             4             4
Lost to Follow-up             0             4             2
Withdrawal by Subject             0             2             3
Other             0             2             3
Arm/Group Title Nonrandomized Double-blind ABT-712 Double-blind Placebo Total
Hide Arm/Group Description 2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks during the open-label period. These participants enrolled in the study and received at least 1 dose of study drug, and either discontinued during the open-label period or were not randomized and did not progress to the double-blind period. 2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period). 2 placebo tablets, twice daily, for 4 weeks (double-blind period). Total of all reporting groups
Overall Number of Baseline Participants 63 109 113 285
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 63 participants 109 participants 113 participants 285 participants
46.1  (12.25) 49.6  (12.44) 48.1  (11.21) 48.2  (11.95)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 63 participants 109 participants 113 participants 285 participants
Female
34
  54.0%
64
  58.7%
59
  52.2%
157
  55.1%
Male
29
  46.0%
45
  41.3%
54
  47.8%
128
  44.9%
Double-blind Baseline CLBP Intensity VAS   [1] 
Mean (Standard Deviation)
Unit of measure:  Scores on a scale
Number Analyzed 63 participants 109 participants 113 participants 285 participants
NA [2]   (NA) 24.2  (15.61) 23.2  (15.01) 23.7  (15.28)
[1]
Measure Description: The last assessment using the CLBP Intensity Visual Analog Scale (VAS) (0 mm = No Pain and 100 mm = Worst Pain Imaginable) conducted before the first dose in the double-blind period.
[2]
These subjects were not randomized to the double-blind period.
Double-blind Baseline Sleep Interference by Pain Scale   [1] 
Mean (Standard Deviation)
Unit of measure:  Scores on a scale
Number Analyzed 63 participants 109 participants 113 participants 285 participants
NA [2]   (NA) 2.2  (2.02) 2.3  (2.16) 2.2  (2.09)
[1]
Measure Description: The last assessment of how much back pain interfered with their sleep on a scale of 0 (not at all) to 10 (completely) conducted before the first dose in the double-blind period.
[2]
These subjects were not randomized to the double-blind period.
1.Primary Outcome
Title Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)
Hide Description The change from the DB randomization baseline (DB baseline: the last assessment before first dose in the DB period) to the final assessment in pain intensity, assessed using the CLBP Intensity VAS (0 mm = No Pain and 100 mm = Worst Pain Imaginable). Least squares means and standard errors from 2-way ANCOVA model without interaction.
Time Frame Double-blind baseline to 4 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis of the primary outcome measure included all randomized participants who received at least 1 dose of study drug during the double-blind period (double-blind intent-to-treat).
Arm/Group Title Double-blind ABT-712 Double-blind Placebo
Hide Arm/Group Description:
2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
2 placebo tablets, twice daily, for 4 weeks (double-blind period).
Overall Number of Participants Analyzed 109 112
Least Squares Mean (Standard Error)
Unit of Measure: scores on a scale
1.2  (2.57) 23.0  (2.54)
2.Secondary Outcome
Title Change From Double-blind (DB) Baseline to Final Assessment in Chronic Pain Sleep Inventory (CPSI)
Hide Description The change from the DB randomization baseline (DB baseline: the last assessment before first dose in the DB period) to the final assessment of the impact of pain on the participant's sleep. The CPSI utilizes a 100 mm VAS scale for questions of how often the participant had trouble falling asleep because of pain, needed sleeping medication, was awakened by pain during the night, and was awakened by pain in the morning (0 mm = Never and 100 mm = Always); and for rating the overall quality of sleep (0 mm = Very Poor and 100 mm = Excellent). Least squares means and standard errors from 2-way ANCOVA model without interaction.
Time Frame Double-blind baseline to 4 weeks
Hide Outcome Measure Data
Hide Analysis Population Description
The analysis of the secondary outcome measure included all randomized participants who received at least 1 dose of study drug during the DB period (DB intent-to-treat), had a DB baseline assessment, and had at least 1 assessment during the DB period.
Arm/Group Title Double-blind ABT-712 Double-blind Placebo
Hide Arm/Group Description:
2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period).
2 placebo tablets, twice daily, for 4 weeks (double-blind period).
Overall Number of Participants Analyzed 106 108
Least Squares Mean (Standard Error)
Unit of Measure: scores on a scale
Trouble Falling Asleep -3.7  (2.75) 18.7  (2.77)
Needed Sleeping Medication -1.2  (2.30) 13.5  (2.32)
Awakened by Pain During the Night -5.0  (2.61) 19.5  (2.63)
Awakened by Pain in the Morning -4.5  (2.72) 20.1  (2.74)
Quality of Sleep -0.4  (3.04) -23.2  (3.06)
Time Frame AEs were recorded from the time of study drug administration to 30 days after last dose (total 12 weeks); SAEs were recorded from the time that informed consent was obtained until 30 days following discontinuation of study drug (total 16 weeks).
Adverse Event Reporting Description AEs with onset during the OL period are shown separately from AEs with onset after the first dose of study drug (ABT-712 or placebo) in the DB period.
 
Arm/Group Title Open-label ABT-712 Double-blind ABT-712 Double-blind Placebo
Hide Arm/Group Description 2 ABT-712 extended-release tablets, twice daily, for up to 3 weeks (open-label period). 2 ABT-712 extended-release tablets, twice daily, for 4 weeks (double-blind period). 2 placebo tablets, twice daily, for 4 weeks (double-blind period).
All-Cause Mortality
Open-label ABT-712 Double-blind ABT-712 Double-blind Placebo
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   --/--   --/--   --/-- 
Hide Serious Adverse Events
Open-label ABT-712 Double-blind ABT-712 Double-blind Placebo
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   1/285 (0.35%)   1/109 (0.92%)   1/113 (0.88%) 
Gastrointestinal disorders       
HAEMORRHOIDS  1  0/285 (0.00%)  0/109 (0.00%)  1/113 (0.88%) 
OBSTRUCTION GASTRIC  1  0/285 (0.00%)  1/109 (0.92%)  0/113 (0.00%) 
PROCTALGIA  1  0/285 (0.00%)  0/109 (0.00%)  1/113 (0.88%) 
Renal and urinary disorders       
RENAL FAILURE ACUTE  1  1/285 (0.35%)  0/109 (0.00%)  0/113 (0.00%) 
Indicates events were collected by systematic assessment
1
Term from vocabulary, MedDRA version 11.1
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Open-label ABT-712 Double-blind ABT-712 Double-blind Placebo
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   146/285 (51.23%)   31/109 (28.44%)   16/113 (14.16%) 
Gastrointestinal disorders       
CONSTIPATION  1  85/285 (29.82%)  4/109 (3.67%)  4/113 (3.54%) 
NAUSEA  1  70/285 (24.56%)  17/109 (15.60%)  4/113 (3.54%) 
VOMITING  1  21/285 (7.37%)  6/109 (5.50%)  2/113 (1.77%) 
Nervous system disorders       
DIZZINESS  1  17/285 (5.96%)  1/109 (0.92%)  1/113 (0.88%) 
HEADACHE  1  19/285 (6.67%)  9/109 (8.26%)  9/113 (7.96%) 
SOMNOLENCE  1  23/285 (8.07%)  4/109 (3.67%)  0/113 (0.00%) 
Skin and subcutaneous tissue disorders       
PRURITUS  1  21/285 (7.37%)  2/109 (1.83%)  0/113 (0.00%) 
Indicates events were collected by systematic assessment
1
Term from vocabulary, MedDRA version 11.1
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Global Medical Services
Organization: AbbVie (prior sponsor, Abbott)
Phone: 800-633-9110
Layout table for additonal information
Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT00763321    
Other Study ID Numbers: M10-277
First Submitted: September 26, 2008
First Posted: September 30, 2008
Results First Submitted: November 1, 2013
Results First Posted: December 23, 2013
Last Update Posted: February 6, 2014